Aptose Secures $10 Million through Facility Agreement with Hanmi
Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS) is a forward-thinking clinical-stage precision oncology company dedicated to creating innovative treatments. Recently, the company reached a significant financial milestone by securing a $10 million loan through a Facility Agreement with Hanmi Pharmaceutical Co. Ltd. This funding is earmarked for the development of tuspetinib, a promising oral kinase inhibitor designed to help patients with acute myeloid leukemia (AML).
Utilization of Funds for Tuspetinib Development
The loan that Aptose has obtained can be converted into milestone obligations tied to a Future Collaboration Agreement. Alternatively, it can be repaid after completing a triple drug combination trial involving tuspetinib in newly diagnosed AML patients. This financial support is crucial for Aptose as it strengthens their commitment to advancing the clinical development of tuspetinib, making significant progress in the battle against AML.
Collaboration with Hanmi to Enhance Product Development
The agreement with Hanmi encompasses more than just financial support. Aptose and Hanmi are currently in discussions to form a new collaboration agreement aimed at co-developing tuspetinib. This partnership is intended to provide additional funding, which will help accelerate the clinical development of this vital treatment. It’s worth noting that Aptose initially licensed tuspetinib from Hanmi back in November 2021, highlighting the strong bond between the two organizations.
About Aptose Biosciences and Their Pipeline
Aptose Biosciences is committed to developing precision medicines that assist clinicians in addressing unmet medical needs in oncology. Their primary focus is on hematology, featuring a diverse portfolio of small molecule cancer therapeutics designed to deliver effective treatment with minimal overlapping toxicities. Tuspetinib, the company’s lead compound, is particularly recognized for its effectiveness both as a standalone treatment and in combination therapies for patients with relapsed or refractory AML. The ongoing development of tuspetinib as part of a frontline treatment option for newly diagnosed AML patients shows great promise.
Looking Ahead: The Future of Tuspetinib
The collaboration agreement with Hanmi represents a crucial advancement for Aptose as the company strives to improve the clinical efficacy of tuspetinib. With Hanmi’s support and a steadfast commitment to innovation, Aptose aims to reshape the treatment landscape for AML, offering hope to numerous patients.
Contact Information for Inquiries
If you would like more information about Aptose and their ongoing developments, please reach out to:
Aptose Biosciences Inc.
Susan Pietropaolo
Corporate Communications & Investor Relations
201-923-2049
spietropaolo@aptose.com
Frequently Asked Questions
What is Aptose Biosciences Inc. known for?
Aptose Biosciences Inc. is known as a clinical-stage precision oncology company that focuses on innovative treatments for hematological cancers, especially acute myeloid leukemia (AML).
How much funding has Aptose recently secured?
Aptose has secured a $10 million loan through a Facility Agreement with Hanmi Pharmaceutical to support the development of tuspetinib.
What is tuspetinib?
Tuspetinib is an oral kinase inhibitor developed by Aptose for treating acute myeloid leukemia (AML), demonstrating efficacy as both a standalone therapy and in combination treatments.
What is the intended use of the funding from Hanmi?
The funding will be utilized for further clinical development of tuspetinib, specifically to support upcoming trials and facilitate its introduction into the market.
How does Aptose plan to collaborate with Hanmi?
Aptose and Hanmi are in the process of negotiating a Future Collaboration Agreement to co-develop tuspetinib, with the goal of enhancing clinical development through shared resources and expertise.
